论文部分内容阅读
目的：分析诱导化疗期骨髓象检查结果与预后的关系。方法：对９６例原发、初治急性髓细胞白血病（ＡＭＬ）患者，于诱导化疗第１疗程期间定时作骨髓穿刺检查。结果：化疗第７天骨髓中幼稚细胞≤０．１０的患者１个疗程完全缓解（ＣＲ）率明显高于幼稚细胞＞０．１０的患者（分别为６４．６％和４０％，Ｐ＜０．０５）。对幼稚细胞＞０．１０的患者适当延长化疗时间可提高１个疗程ＣＲ率（５０％∶２５％，但与不延长化疗组相比无统计学差异）。停化疗后ＷＢＣ降至最低时骨髓中幼稚细胞比例和预后更具显著相关性，幼稚细胞≤０．１０的患者１个疗程ＣＲ率明显高于幼稚细胞＞０．１０的病例（６６．０％∶２５．８％，Ｐ＜０．００５），而难治病例发生率显著减少（７．５％∶４５．２％，Ｐ＜０．００５）。结论：诱导化疗期定时骨髓象检查有助于估计预后、指导治疗和改善疗效。
Objective: To analyze the relationship between bone marrow findings and prognosis in induction chemotherapy. METHODS: Ninety-six patients with primary and newly diagnosed acute myeloid leukemia (AML) were subjected to bone marrow biopsy during the first course of induction chemotherapy. RESULTS: The complete remission (CR) rate was significantly higher in patients with immature cells <0.10 in bone marrow on day 7 after chemotherapy than in patients with immature cells >0.10 (64.6% and 40%, respectively), P<0. .05). Prolonging the chemotherapy time for patients with a naïve cell > 0.10 increased the CR rate by 1 course (50%: 25%, but was not statistically different from the non-prolonged chemotherapy group). The percentage of immature cells in the bone marrow was significantly correlated with the prognosis when WBC was reduced to a minimum after chemotherapy was stopped. The CR rate of one course of treatment for patients with immature cells ≤ 0.10 was significantly higher than that of cases with immature cells > 0.10 (66.0%). : 25.8%, P<0.005), while the incidence of refractory cases was significantly reduced (7.5%: 45.2%, P<0.005). CONCLUSIONS: Timed bone marrow imaging during induction chemotherapy can help estimate prognosis, guide treatment, and improve outcomes.